A phase 2 clinical study of RZ402, a potential oral therapy for diabetic macular edema, met its primary endpoints of safety and reduction in central subfield thickness, according to a press release from Rezolute.
The multicenter, randomized, double-masked, placebo-controlled, parallel-arm, proof-of-concept study enrolled 94 DME participants with mild to moderate nonproliferative diabetic retinopathy who had received no more than three anti-VEGF injections previously. Central subfield thickness (CST) was 320 µm or greater in men and 305 µm or greater in women. All participants had